VioQuest Pharmaceuticals, Inc.
VOQP
Other OTC0.00
USD
- -
- -
VioQuest Pharmaceuticals, Inc.
VOQP
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- VioQuest Pharmaceuticals, Inc. VioQuest Pharmaceuticals, Inc. (VOQP), a biopharmaceutical company founded in 2000 and headquartered in Basking Ridge, New Jersey, focuses on the acquisition, development, and commercialization of clinical-stage drug therapies for oncology and infectious diseases; its lead product candidate, Xyfid (1% topical uracil), targets the treatment and prevention of hand-foot syndrome, dry skin conditions, and associated dermatoses; additional pipeline assets include VQD-002 (triciribine phosphate monohydrate, or TCN-P), a nucleoside analog and Akt inhibitor in Phase I trials for various solid and hematologic cancers including breast, ovarian, colorectal, pancreatic, and liquid tumors; and Lenocta (sodium stibogluconate), a small molecule inhibitor of protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B in Phase IIa trials for melanoma, renal cell carcinoma, and other solid tumors. The company also historically provided chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical firms across product lifecycles through its former Chiral Quest subsidiary, which it sold in 2007 for up to $3 million to strengthen its drug development focus. VioQuest Pharmaceuticals, Inc. operates primarily in the United States with a lean structure of approximately three employees and targets unmet needs in cancer treatment side effects and molecular oncology pathways. In recent years, the company has faced significant challenges, including a 2008 cash crunch that led to a strategic alternatives review, executive resignations, and halted SEC filings amid unsuccessful fundraising and partnership efforts; it maintains a dormant OTC Pink Sheets listing with negligible market capitalization but shows no evidence of active operations, recent product advancements, acquisitions, funding, or clinical trial progress as of 2025.